223 related articles for article (PubMed ID: 25099079)
21. Neurocognitive functioning in patients with bipolar I disorder recently recovered from a first manic episode.
Torres IJ; DeFreitas VG; DeFreitas CM; Kauer-Sant'Anna M; Bond DJ; Honer WG; Lam RW; Yatham LN
J Clin Psychiatry; 2010 Sep; 71(9):1234-42. PubMed ID: 20361907
[TBL] [Abstract][Full Text] [Related]
22. [Neurocognitive function in clinically stable patients with schizophrenia or bipolar disorder and normal controls].
Konstantakopoulos G; Ioannidi N; Patrikelis P; Soumani A; Oulis P; Sakkas D; Papadimitriou GN; Ploumpidis D
Psychiatriki; 2011; 22(3):195-206. PubMed ID: 21971195
[TBL] [Abstract][Full Text] [Related]
23. The effect of erythropoietin on cognition in affective disorders - Associations with baseline deficits and change in subjective cognitive complaints.
Ott CV; Vinberg M; Kessing LV; Miskowiak KW
Eur Neuropsychopharmacol; 2016 Aug; 26(8):1264-73. PubMed ID: 27349944
[TBL] [Abstract][Full Text] [Related]
24. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
25. Impact of pretreatment interhemispheric hippocampal asymmetry on improvement in verbal learning following erythropoietin treatment in mood disorders: a randomized controlled trial.
Miskowiak KW; Forman JL; Vinberg M; Siebner HR; Kessing LV; Macoveanu J
J Psychiatry Neurosci; 2020 May; 45(3):198-205. PubMed ID: 31804779
[TBL] [Abstract][Full Text] [Related]
26. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
[TBL] [Abstract][Full Text] [Related]
27. Effects of erythropoietin on memory-relevant neurocircuitry activity and recall in mood disorders.
Miskowiak KW; Macoveanu J; Vinberg M; Assentoft E; Randers L; Harmer CJ; Ehrenreich H; Paulson OB; Knudsen GM; Siebner HR; Kessing LV
Acta Psychiatr Scand; 2016 Sep; 134(3):249-59. PubMed ID: 27259062
[TBL] [Abstract][Full Text] [Related]
28. A five-year follow-up study of neurocognitive functioning in bipolar disorder.
Santos JL; Aparicio A; Bagney A; Sánchez-Morla EM; Rodríguez-Jiménez R; Mateo J; Jiménez-Arriero MÁ
Bipolar Disord; 2014 Nov; 16(7):722-31. PubMed ID: 24909395
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study.
Calabrese JR; Keck PE; Starace A; Lu K; Ruth A; Laszlovszky I; Németh G; Durgam S
J Clin Psychiatry; 2015 Mar; 76(3):284-92. PubMed ID: 25562205
[TBL] [Abstract][Full Text] [Related]
30. Effects of N-acetyl cysteine on cognitive function in bipolar disorder.
Dean OM; Bush AI; Copolov DL; Kohlmann K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Berk M
Psychiatry Clin Neurosci; 2012 Oct; 66(6):514-7. PubMed ID: 23066769
[TBL] [Abstract][Full Text] [Related]
31. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study.
Stamm TJ; Lewitzka U; Sauer C; Pilhatsch M; Smolka MN; Koeberle U; Adli M; Ricken R; Scherk H; Frye MA; Juckel G; Assion HJ; Gitlin M; Whybrow PC; Bauer M
J Clin Psychiatry; 2014 Feb; 75(2):162-8. PubMed ID: 24345793
[TBL] [Abstract][Full Text] [Related]
32. Effects of erythropoietin on cognitive impairment and prefrontal cortex activity across affective disorders: A randomized, double-blinded, placebo-controlled trial.
Macoveanu J; Petersen JZ; Mariegaard J; Jespersen AE; Cramer K; Bruun CF; Madsen HØ; Jørgensen MB; Vinberg M; Fisher PM; Knudsen GM; Hageman I; Ehrenreich H; Kessing LV; Miskowiak KW
J Psychopharmacol; 2024 Apr; 38(4):362-374. PubMed ID: 38519416
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME
Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071
[TBL] [Abstract][Full Text] [Related]
34. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen.
Yildiz A; Guleryuz S; Ankerst DP; Ongür D; Renshaw PF
Arch Gen Psychiatry; 2008 Mar; 65(3):255-63. PubMed ID: 18316672
[TBL] [Abstract][Full Text] [Related]
35. Low compliance to pharmacological treatment is linked to cognitive impairment in euthymic phase of bipolar disorder.
Fuentes I; Rizo-Méndez A; Jarne-Esparcia A
J Affect Disord; 2016 May; 195():215-20. PubMed ID: 26897294
[TBL] [Abstract][Full Text] [Related]
36. The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study.
Vinberg M; Miskowiak K; Hoejman P; Pedersen M; Kessing LV
PLoS One; 2015; 10(5):e0127629. PubMed ID: 26011424
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.
Suppes T; McElroy SL; Sheehan DV; Hidalgo RB; Cosgrove VE; Gwizdowski IS; Feldman NS
J Clin Psychiatry; 2014 Jan; 75(1):77-84. PubMed ID: 24345758
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and cognitive side effects after brief pulse and ultrabrief pulse right unilateral electroconvulsive therapy for major depression: a randomized, double-blind, controlled study.
Spaans HP; Verwijk E; Comijs HC; Kok RM; Sienaert P; Bouckaert F; Fannes K; Vandepoel K; Scherder EJ; Stek ML; Kho KH
J Clin Psychiatry; 2013 Nov; 74(11):e1029-36. PubMed ID: 24330903
[TBL] [Abstract][Full Text] [Related]
40. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia.
Ringen PA; Vaskinn A; Sundet K; Engh JA; Jónsdóttir H; Simonsen C; Friis S; Opjordsmoen S; Melle I; Andreassen OA
Psychol Med; 2010 Aug; 40(8):1337-47. PubMed ID: 19891810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
